glp-1 and seizures Drugs Linked to Lower Epilepsy Risk in Diabetes Patients Neuroprotective effects of glucagon-like peptide-1

Long-term safety data in the pediatric population is still limited, and ongoing surveillance is crucial to identify potential long-term effects on growth and development

Semaglutide Customized Compounded Medical Weight Loss In Stock GLP-1 *priced by total mg per vial Prescription GLP-1 Plus Personalized Plans Online medical support All-inclusive package you pay for the treatment, we cover the rest

What the science says Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout doi: References Wharton, S

Another 2024 study found that people with breast cancer and type 2 diabetes taking GLP-1 drugs had fewer major cardiovascular problems (conditions related to heart and blood vessels) after receiving cardiotoxic breast cancer treatments such as anthracyclines and HER2 inhibitors, compared to people not taking GLP-1 drugs

Two people taking the same medication can have very different experiences